TYROS BIOPHARMA

newsroom

We believe in helping women own their day

Tyros Biopharma is pleased to announce that URIEXO for the prevention of Urinary Tract Infections and its associated symptoms (painful or difficult urination, frequent urination, urgency to urinate, and suprapubic pain), is now available at all Rexall locations across Canada.

Rexall Pharmacy Group Ltd. is a chain of retail pharmacies in Canada operating as Rexall and Rexall Pharma Plus with over 400 stores across Ontario and Western Canada. “We are very excited to welcome Shoppers Drug Mart as the newest member of our distribution network,” says Anthony Gouvoussis, President for Tyros Biopharma.

URIEXO®, a novel treatment with two active ingredients to help prevent recurrent urinary infections and its associated symptoms (painful or difficult urination, frequent urination, urgency to urinate, and suprapubic pain), has been reviewed and approved to be part of the new “Brand Recognition Program” recently introduced by the Society of Obstetricians and Gynaecologists of Canada (SOGC).
The SOGC Brand Recognition Program aims to assist Canadian consumers to make informed choices when selecting over-the-counter products. This program is designed for non-prescription/over-the-counter products that are found to safely and effectively promote female sexual and reproductive health. Eligible products are required to have:
  • Received Health Canada approval for sale in the Canadian market;
  • Demonstrated reasonable evidence of safety and efficacy, and pose no undue harm;
  • Substantiated packaging claims and a perceived low risk.
  • Products are independently and carefully reviewed by a panel of medical professionals. “URIEXO® is manufactured in Canada and will be available without a prescription across Canada in the feminine hygiene sections at participating pharmacies, within the next few weeks. URIEXO® is also immediately available online at amazon.ca” concluded Lee Alexander Sciortino, Vice-President of Commercial Operations.
    The new website for URIEXO tackles of the issues, social stigmas, taboos, misconceptions and challenges Canadian face when dealing with Urinary Tract Infections (UTIs) and its symptoms.
    Urinary tract infections (UTIs) are a very common infection that affects any part of the urinary system, which is made up of your kidneys, ureters, bladder, and urethra. Most UTIs are caused by bacteria from the digestive tract, such as E. coli, which are responsible for around 90% of UTI causes, but some are caused by fungi and in rare cases by viruses. Although some bacteria are flushed away when you urinate, some will attach to the wall of your urethra or bladder and once attached, they can quickly multiply into an infection. Left untreated, the infection can move from the bladder to the kidneys and do even more harm.
    “This new website will provide Canadians with essential information they should know on how to treat and prevent urinary tract infections and will potentially help Canadians avoid unnecessarily using antibiotics for uncomplicated urinary tract infections” says Lee Alexander Sciortino, Vice-President of Commercial operations at Tyros Biopharma Inc.
    “URIEXO® is manufactured in Canada and will be available without a prescription across Canada in the feminine hygiene sections at participating pharmacies, within the next few weeks. URIEXO® is also immediately available online at amazon.ca” concluded Lee Alexander Sciortino, Vice-President of Commercial Operations.
    URIEXO® Double Action is UNIQUE in that it has a double mode of action. Specially formulated with not one but two clinically active ingredients, D-Mannose and Proanthocyanidins (PACs), sourced from cranberry, URIEXO® provides Canadians with a two-pronged and scientifically proven defence, against recurring UTIs. These two active ingredients bind with UTI-causing bacteria in the urinary tract in two separate and distinct ways, preventing bacteria from sticking to your bladder wall and urinary tract, so that sufferers can safely flush bacteria out of your system.
    Urinary tract infections (UTIs) are a very common infection that affects any part of the urinary system, which is made up of your kidneys, ureters, bladder, and urethra. Most UTIs are caused by bacteria from the digestive tract, such as E. coli, which are responsible for around 90% of UTI causes, but some are caused by fungi and in rare cases by viruses. Although some bacteria are flushed away when you urinate, some will attach to the wall of your urethra or bladder and once attached, they can quickly multiply into an infection. Left untreated, the infection can move from the bladder to the kidneys and do even more harm. Most UTIs only involve the urethra and bladder, in the lower tract, however, UTIs can involve the ureters and kidneys, in the upper tract. Although upper tract UTIs are rarer than lower tract UTIs, they’re also usually more severe and require immediate medical attention.
    URIEXO® is UNIQUE in that it has a double mode of action. Specially formulated with not one but two clinically active ingredients, D-Mannose and Proanthocyanidins (PACs) sourced from cranberry, URIEXO® provides you with a two-pronged and scientifically proven defence against recurring UTIs. D-Mannose is a naturally occurring sugar similar in structure to but metabolized differently from glucose so that it does not negatively impact glycemic (blood sugar) control. PACs are a type of polyphenol, a plant-based micronutrient full of antioxidants. It can be found in many fruits, but cranberries have an especially high concentration of PACs.
    URIEXO® works by binding to two different types of receptors or anchoring sites (surface proteins) called pili found on surface of bacteria. The pili normally help E. coli bacteria to firmly attach themselves to the cells in the urinary tract, making it very difficult for the body to naturally flush the bacteria from the urinary tract. By targeting and binding to these two different types of pili proteins, URIEXO® prevents bacteria from attaching themselves to the lining of the urinary tract. The bound bacteria-URIEXO® compound is then flushed out naturally with normal urination. Lee Alexander Sciortino, Vice-President of Commercial Operations at Tyros Biopharma Inc, explains that “Recurrent urinary tract infections are very common among women and account for approximately 20% of all infections in women. In fact, 1 in 2 women will have at least one UTI in their lifetime and after a UTI, 20-40% of these women will continue to have recurrences which can last for years on end. URIEXO® is UNIQUE in that it gives your body a two-pronged defence to fight off bacteria, by binding to two different types of receptors on the bacterial surface thereby preventing them from binding to cell walls so you can safely flush them out.”
    URIEXO® is manufactured in Canada and will be available without a prescription across Canada in the feminine hygiene sections at participating pharmacies, within the next few weeks.
    New non-prescription URIEXO® is a clinically proven, non-antibiotic option to UTI prevention. Only URIEXO® Double-Action is specially formulated with two clinically proven active ingredients (2000 mg of D-Mannose and 36 mg of PACs in its daily recommended dose) that have been demonstrated to be effective as prophylactic therapy for patients with recurrent urinary tract infections (UTIs).
    URIEXO® provides patients with a two-pronged and scientifically proven defence, against recurring UTIs. These two active ingredients, bind with UTI-causing bacteria in the urinary tract in two separate ways, preventing bacteria from adhering to the bladder wall and urinary tract, so that bacteria can safely be flushed out with urination. This double mode of action helps prevent the pain associated with urinary tract infections, and more importantly, protects patient’s kidneys from potential damage of recurring UTIs.
    According to Lee Alexander Sciortino, Vice-President of Commercial Operations at Tyros Biopharma, “Recurrent urinary tract infections are very common among women and account for approximately 20% of all infections in women. In fact, 1 in 2 women will have at least one UTI in their lifetime and after a UTI, 20-40% of these women will continue to have recurrences which can last for years on end. URIEXO® is UNIQUE in that it gives your body a two-pronged defence to fight off bacteria, by binding to two different types of receptors on the bacterial surface thereby preventing them from binding to cell walls so you can safely flush them out.”
    URIEXO® is manufactured in Canada and will be available without a prescription across Canada in the feminine hygiene sections at participating pharmacies, within the next few weeks.

    The new website for GYNALAC® tackles some of the issues, social stigmas, taboos, misconceptions and challenges women face when dealing with vaginal odor and other symptoms of Bacterial Vaginosis. It provides women with the essential information they should know on how to treat and prevent vaginal odour and other symptoms of Bacterial Vaginosis as well as helpful tips on how to deal with vaginal odor and symptoms of Bacterial Vaginosis.

    The new website for GYNATROF® tackles some of the issues, social stigmas, taboos, misconceptions and challenges women face when dealing with intimate dryness and other symptoms of vulvovaginal atrophy. It arms women with essential information they should know to treat and prevent vaginal dryness and other symptoms of vaginal atrophy.

    GYNALAC®, a novel treatment to help women overcome their recurrent Bacterial Vaginosis, has been reviewed and approved to be part of the new “Brand Recognition Program” recently introduced by the Society of Obstetricians and Gynaecologists of Canada (SOGC).

    The SOGC Brand Recognition Program aims to assist Canadian consumers to make informed choices when selecting over-the-counter products. This program is designed for non-prescription/over-the-counter products that are found to safely and effectively promote female sexual and reproductive health.

    Eligible products are required to have:
    • Received Health Canada approval for sale in the Canadian market;
    • Demonstrated reasonable evidence of safety and efficacy, and pose no undue harm;
    • Substantiated packaging claims and a perceived low risk.

    Products are independently and carefully reviewed by a panel of medical professionals. “GYNALAC® is manufactured in Canada and will be available without a prescription across Canada in the feminine hygiene sections at participating pharmacies, within the next few weeks. GYNALAC® is also immediately available online at amazon.ca” concluded Lee Alexander Sciortino, Vice-President of Commercial Operations.

    GYNALAC®, a novel treatment to help women overcome their recurrent Bacterial Vaginosis, is now available in Canada.

    Bacterial vaginosis is the most common lower genital tract disorder among women of reproductive age (pregnant and non-pregnant) and the most prevalent cause of vaginal discharge and malodour. It has been associated with a significant number of obstetric and gynaecologic complications, such as preterm labour and delivery, premature rupture of membranes, spontaneous abortion, chorioamnionitis, postpartum endometritis, post-Caesarean delivery wound infections, postsurgical infections, and subclinical pelvic inflammatory disease.

    GYNALAC® is a double-acting vaginal gel, which contains a unique formulation of both lactic acid and sodium hyaluronate, and is clinically proven to treat acute episodes of Bacterial Vaginosis and prevent their recurrences. Lactic acid is naturally produced by friendly bacteria (Lactobacillus) in a woman’s vagina and is the cornerstone in the normal maintenance of the vaginal ecosystem by contributing to the reestablishment of the natural vaginal flora. Presence in adequate amounts ensures the maintenance of an acidic vaginal pH, where Lactobacilli (friendly bacteria) can adequately proliferate and correctly metabolize. Clinical evidence shows that a treatment course of lactic acid helps to relieve and prevent symptoms of BV, thereby bringing a natural protection against intimate irritation. Sodium hyaluronate is a compound that is also naturally produced by a woman’s body. Sodium hyaluronate has a long lasting moisturizing effect and promotes wound healing by enabling cells to retain moisture in the tissue. These two natural ingredients are delivered directly into the vagina where they can restore the natural flora and help protect against odor.

    Anthony Gouvousis, president of Tyros Biopharma, explains that “Bacterial Vaginosis is the most common cause of vaginal infections and is about twice as common as Yeast infections. It is estimated that up to 29% of women in North America can be infected and can be found in up to 25% of pregnant women. This type of infection occurs when the healthy balance between the “good” and the “bad” bacteria in the vaginal ecosystem becomes disrupted due to various external or physiological risk factors. When the number of protective bacteria (Lactobacilli) decreases, “bad” bacteria (such as Gardnerella) overgrow and BV symptoms occur. Bacterial vaginosis is usually not dangerous, however if left untreated it can increase the risk for other medical problems, including post-operative infections and pregnancy related complications. ”

    GYNALAC® is manufactured in Canada and will be available without a prescription across Canada in the feminine hygiene sections at participating pharmacies, within the next few weeks.

    Tyros Biopharma is pleased to announce that GYNALAC®, a non-antibiotic treatment to relieve and prevent symptoms of Bacterial Vaginosis and non-specific vaginitis, is now available at all Jean Coutu locations across Quebec.

    Jean Coutu is the largest retail pharmacy chain in Quebec, with more than 400 stores in the province. “We are very excited to welcome Jean Coutu as the newest member of our distribution network,” says Anthony Gouvoussis, President of Tyros Biopharma.

    Tyros Biopharma is pleased to announce that GYNALAC®, a non-antibiotic treatment to relieve and prevent symptoms of Bacterial Vaginosis and non-specific vaginitis, is now available at all Shoppers Drug Mart/Pharmaprix locations across Canada.

    Shoppers Drug Mart is the largest retail pharmacy chain in Canada, with more than 1,253 stores from coast to coast. “We are very excited to welcome Shoppers Drug Mart as the newest member of our distribution network,” says Lee Alexander Sciortino, Vice-President of Commercial Operations for Tyros Biopharma.

    GYNALAC®, a novel treatment to help women overcome their recurrent Bacterial Vaginosis, is now approved in Canada.

    Bacterial vaginosis is the most common lower genital tract disorder among women of reproductive age (pregnant and non-pregnant) and the most prevalent cause of vaginal discharge and malodour. It has been associated with a significant number of obstetric and gynaecologic complications, such as preterm labour and delivery, premature rupture of membranes, spontaneous abortion, chorioamnionitis, postpartum endometritis, post-Caesarean delivery wound infections, postsurgical infections, and subclinical pelvic inflammatory disease.

    GYNALAC® is a double-acting vaginal gel, which contains a unique formulation of both lactic acid and sodium hyaluronate, and is clinically proven to treat acute episodes of Bacterial Vaginosis and prevent their recurrences. Lactic acid is naturally produced by friendly bacteria (Lactobacillus) in a woman’s vagina and is the cornerstone in the normal maintenance of the vaginal ecosystem by contributing to the reestablishment of the natural vaginal flora. Presence in adequate amounts ensures the maintenance of an acidic vaginal pH, where Lactobacilli (friendly bacteria) can adequately proliferate and correctly metabolize. Clinical evidence shows that a treatment course of lactic acid helps to relieve and prevent symptoms of BV, thereby bringing a natural protection against intimate irritation. Sodium hyaluronate is a compound that is also naturally produced by a woman’s body. Sodium hyaluronate has a long lasting moisturizing effect and promotes wound healing by enabling cells to retain moisture in the tissue. These two natural ingredients are delivered directly into the vagina where they can restore the natural flora and help protect against odor.

    According to Lee Alexander Sciortino, Vice-President of Commercial Operations at Tyros Biopharma, “GYNALAC® not only provides a novel solution to treat acute episodes of Bacterial Vaginosis, but is also clinically proven, in prophylaxis, to prevent recurrences of Bacterial Vaginosis. Recurrence rates after antibiotic treatment in excess of 70% after 6 months have been described, even after successful antibiotic treatment. One possible explanation for the high rate of recurrence is that antibiotic treatment does not re-establish the protective lactobacilli following therapy. Developing a routine with GYNALAC® helps a woman maintain the natural vaginal pH balance and prevent these recurrences.”

    GYNATROF®, a non-hormonal vaginal moisturizer indicated for the immediate relief of dryness, itching, burning & painful sexual activity, associated with vaginal atrophy, has been reviewed and approved to be part of the new “Brand Recognition Program” recently introduced by the Society of Obstetricians and Gynaecologists of Canada (SOGC).

    The SOGC Brand Recognition Program aims to assist Canadian consumers to make informed choices when selecting over-the-counter products. This program is designed for non-prescription/over-the-counter products that are found to safely and effectively promote female sexual and reproductive health.

    Eligible products are required to have:
    • Received Health Canada approval for sale in the Canadian market.
    • Demonstrated reasonable evidence of safety and efficacy, and pose no undue harm.
    • Substantiated packaging claims and a perceived low risk.

    Products are independently and carefully reviewed by a panel of medical professionals.

    GYNATROF® is available without a prescription across Canada in the feminine hygiene sections at participating pharmacies.

    Tyros Biopharma is pleased to announce that GYNATROF® , a non-hormonal gel for the treatment of vaginal atrophy, is now available at all Shoppers Drug Mart/Pharmaprix locations across Canada. Shoppers Drug Mart the largest retail pharmacy chain in Canada, with more than 1,253 stores from coast to coast. “We are very excited to welcome Shoppers Drug Mart as the newest member of our distribution network,” says Anthony Gouvoussis, President of Tyros Biopharma. “For the first time, GYNATROF® will be available to women nationwide to relieve and treat the many uncomfortable symptoms of vaginal atrophy.” In 2013, Jean Coutu and Brunet were the first two pharmacy chains in Canada to list GYNATROF® . In recent months, a number of other regional chains have come on board, including: ARP, Proxim, IDA, Guardian, Uniprix, Familiprix, Family Health Care and Medicine Shoppe. Gynatrof is also available nationwide at Costco Pharmacy and online at Well.ca.

    Tyros Biopharma is pleased to announce that GYNATROF® , a non-hormonal gel for the treatment of vaginal atrophy is now available in Brunet pharmacies across Quebec. Brunet operates a network of close to 200 pharmaceutical establishments under the banners: Brunet, Brunet Plus, Brunet Clinique and Clini Plus.

    Tyros Biopharma is pleased to announce that, GYNATROF® , a non-hormonal gel for the treatment of Vaginal Atrophy is now available in Jean Coutu pharmacies across Quebec. Jean Coutu is the first pharmacy chain in Canada to list GYNATROF® . The product will be available of the shelf in two formats: 15 ml and 50 ml.

    Tyros Biopharma is pleased to announce that Health Canada has licensed their first product, GYNATROF®, a non-hormonal gel for the treatment of Vaginal Atrophy and the associated symptoms of dryness, itching, burning and painful sexual activity. GYNATROF® will be available for sale in Canada in July 2013.

    Welcome to Tyrosbiopharma.com, our home on the web for all the latest news and hot topics in women’s health.

    A new pharmaceutical company committed to changing the face of women’s health was launched today in Canada. Montreal-based Tyros Biopharma plans to provide therapeutic alternatives with proven results that address the limitations in most treatment options available to menopausal women today. Tyros is currently developing its product portfolio, and anticipates Health Canada approval of its first product by October 2012.